ANTX
AN2 Therapeutics Inc
NASDAQ: ANTX · HEALTHCARE · BIOTECHNOLOGY
$4.47
-1.76% today
Updated 2026-11-16
Market cap
$168.85M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.91
Dividend yield
—
52W range
$1 – $7
Volume
0.3M
WallStSmart proprietary scores
27
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C4.8
Quality
C3.0
Profitability
D5.0
Valuation
C+1/9
Piotroski F-Score
Weak
-2.9
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →252 stocks currently score above 75
Price targets
Analyst target
$9.00
+101.34%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy2 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
Insufficient data
Risks
- Piotroski 1/9 — weak financial health
- Altman Z -2.90 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-6.10M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-41.47M | $-64.73M | $-51.32M | $-35.17M | $-7.96M |
| EPS | — | — | — | — | $-0.91 |
| Free cash flow | $-33.46M | $-53.29M | $-49.26M | $-29.83M | $-6.10M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
AN2 Therapeutics Inc trades at $4.47. Our Smart Value Score of 27/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -2.90, it sits in the distress.
Frequently asked questions
What is AN2 Therapeutics Inc's stock price?
AN2 Therapeutics Inc (ANTX) trades at $4.47.
Is AN2 Therapeutics Inc overvalued?
AN2 Therapeutics Inc carries a Smart Value Score of 27/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of AN2 Therapeutics Inc (ANTX)?
The 12-month analyst consensus target is $9.00, about 101.3% above the current $4.47. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
AN2 Therapeutics Inc's Altman Z-Score is -2.90, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-42.26%
Beta-0.94
50D MA$4.64
200D MA$4.21
Shares out0.04B
Float0.02B
Short ratio—
Avg volume0.3M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—